Market Research Report
Global Colorectal Cancer Therapeutics Market 2022-2026
|Global Colorectal Cancer Therapeutics Market 2022-2026|
Published: March 14, 2022
TechNavio (Infiniti Research Ltd.)
Content info: 120 Pages
Delivery time: 1-2 business days
Technavio has been monitoring the colorectal cancer therapeutics market and it is poised to grow by $ 2.45 bn during 2022-2026 progressing at a CAGR of 5.43% during the forecast period. Our report on the colorectal cancer therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing geriatric population, rising occurrence of colorectal cancer, and introduction of combination therapeutics.
The colorectal cancer therapeutics market analysis includes type segment and geographic landscape.
Technavio's colorectal cancer therapeutics market is segmented as below:
By Geographical Landscape
This study identifies the development of small molecule kinase inhibitors as one of the prime reasons driving the colorectal cancer therapeutics market growth during the next few years. Also, the advent of gene therapy and personalized therapeutics will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the colorectal cancer therapeutics market covers the following areas:
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading colorectal cancer therapeutics market vendors that include Accord Healthcare Ltd., Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol-Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE, and Co. KGaA, Hetero Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. Also, the colorectal cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.